Companies › Avalyn Pharma
2 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Immunology, Respiratory, Cardiovascular, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| AP01 Pirfenidone; antifibrotic agent | – | Phase 2 | Pulmonary Fibrosis; Progressive Pulmonary Fibrosis | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03377023 | Nintedanib (AP02) | Phase 1 | Non Small Cell Lung Cancer | Oncology | Nov 2023 |
| NCT06071013 | Nintedanib (AP02) | Phase 1 | Non-small Cell Lung Cancer | Oncology | Aug 2026 |
| NCT07194382 | Nintedanib (AP02) | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Dec 2026 |
| NCT04976036 | Nintedanib (AP02) | Phase 2 | Telangiectasia, Hereditary Hemorrhagic | Cardiovascular | Dec 2026 |
| NCT03513484 | Nintedanib (AP02) | Phase 1 | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Oncology | Jan 2027 |
| NCT06329401 | AP01 | Phase 2 | Pulmonary Fibrosis | Immunology | Jun 2027 |
| NCT06297096 | Nintedanib (AP02) | Phase 3 | Systemic Sclerosis | Immunology | Dec 2027 |
| NCT06951217 | AP01 | Phase 2 | Progressive Pulmonary Fibrosis | Respiratory | Dec 2031 |
Cash and short-term investments of $352m on 2026-06-30; operating cash outflow about $113m a year; runway about 37 months at that burn, to Aug 2029; 4 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Enanta Pharmaceuticals Cumberland Pharmaceuticals Prana Therapies Enveda Therapeutics Palisade Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.